Conflicts of Interest – AZ – Explore EVERY angle

Conflicts of Interest – AZ

on October 30, 2021 IN CONflict$

Updated:5 months ago
Reading Time:13Minutes
Post Words:3183Words

Just having a look at the Listed Conflicts on the AstraZeneca Trial Analysis Data 👀

(I mean you wouldn’t want Independent Researchers looking into it before it got mandated to the entire world or anything? “If the people who make it say it’s safe & effective, it must be safe & effective” – let’s just roll up our sleeves then)

Vaccitech is an Oxford University spin-out company that owns the biotechnology behind the AstraZeneca Vaccine.
- The company was founded in 2016 as a University spin-off by Sarah Gilbert and Adrian V. S. Hill at the Jenner Institute, University of Oxford.
- Vaccitech has been financed and supported by Google Ventures (GV), Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation (OSI).
International Trials sponsored by University of Oxford – lead by Andrew Pollard
Andrew Pollard ^{⁽⁰¹⁾Andrew J Pollard – Prof of Paediatric Infection & Immunity – Director of The Oxford Vaccine Group – Member of the World Health Organisation’s SAGE, Chair of UK Health Department’s Joint Committee on Vaccination and … Click for full citation}
- Director of The Oxford Vaccine Group
- Oxford Vaccine Group (OVG) who receive funding from vaccine manufacturers for their trials.
- Member of WHO SAGE since 2016 ^{⁽⁰²⁾WHO – SAGE – Immunization, Vaccines and Biologicals – Current SAGE Members (Archive.org copy) – Original URL keeps getting redirected to a “we are revamping our website” notice since April 25, 2021 … Click for full citation}
- Chair of UK health Dept. Vaccination Committee
- Chair of The Joint Committee on Vaccination & Immunisation (JCVI) ^{⁽⁰³⁾ Joint Committee Andrew Pollard on Vaccination and Immunisation: https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#membership}who advises WHO & UK health departments on immunisation.
- Lead developer of the Bexsero meningococcal B vaccine, previously owned by Novartis and now owned by GSK
Oxford University receives funding from Vaccine Manufacturing and Innovation Centre UK [20, p.81]. ^{⁽⁰⁴⁾ Financial Statements 2018/19 University of Oxford | PDF P.81}
- Oxford University Innovation (Hong Kong) Limited has entered into a joint venture with the Changzhou government in China.
- Oxford University Innovation (Hong Kong) Limited has established a Sino-foreign joint venture in partnership with the Suzhou city government and Oxlink Investment Consulting Co. Ltd (Oxlink), Oxlink is a company registered in PRC.
- Oxford University Innovation (Hong Kong) Limited has established a Sino-foreign joint venture in partnership with Shenzhen City Jinyucheng Science & Technology Co. Ltd (Jinyucheng), and Shenzhen City Guochuang Lianhe Science & Technology Investment Co. Ltd (Guochuang). Jinyucheng and Guochuang are companies registered in PRC.
Competing interests listed in the “Safety analysis” of the International trials of the AZ vaccine ^{⁽⁰⁵⁾Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust … Click for full citation}

Financial Statements 2018/19 University of Oxford

Declared Competing-Interests in the AZ Trials Analysis

Oxford University – Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. ^{⁽⁰⁸⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation}
- Oxford University could also collect a big windfall, as it holds a 5.4% stake directly. It also owns further stakes through the university’s spin-out holding company, Oxford Sciences Innovation (OSI). ^{⁽⁰⁹⁾ AstraZeneca vaccine scientists set for £22m payday in New York float – Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public – TheGuardian – Apr 8, 2021}
Alexander D Douglas – ADD reports grants and personal fees from AstraZeneca, outside of the submitted work. ^{⁽¹⁰⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation}
^{Pedro M Folegatti – Consultant to Vaccitech during the conduct of the study. ⁽¹¹⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation}
Adam Finn – Member of the JCVI
- Chair of the WHO European Technical Advisory Group of Experts.
- Grants from Pfizer
- Grants from GlaxoSmithKline
- Grants from Sanofi
- Grants from Merck Sharp & Dohme
- Grants from Valneva. ^{⁽¹²⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation}
Sarah C Gilbert – co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine (PCT/GB2012/000467). ^{⁽¹³⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation}
- Prof Sarah Gilbert, scientist who led the team that created the Oxford/AstraZeneca coronavirus vaccine, is set for a payday of more than £20m as the biotech firm she co-founded prepares to float on the stock market in the US.
- Gilbert owns 5.2% of Vaccitech, a Oxford University spin-out company that owns the biotechnology behind the AstraZeneca vaccine and others for MERS, hepatitis B, and a range of cancers. ^{⁽¹⁴⁾AstraZeneca vaccine scientists set for £22m payday in New York float – Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public – TheGuardian – Apr 8, 2021}
Catherine M Green – Clinical BioManufacturing Facility, University of Oxford, Oxford, UK.
- During the COVID-19 pandemic Green was part of the Oxford team who developed the Oxford–AstraZeneca COVID-19 vaccine. ^{⁽¹⁵⁾Catherine M. Green – Wikipedia}
- Reports personal fees from the Duke Human Vaccine Institute, outside of the submitted work. ^{⁽¹⁶⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation}
Hill AVS – AVSH reports personal fees from Vaccitech, outside of the submitted work, and has a patent on ChAdOx1 licensed to Vaccitech (PCT/GB2012/000467), will from royalty income to the University of Oxford from sales of this vaccine by AstraZeneca and sublicensees. ^{⁽¹⁷⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation Adrian Hill’s stakes could be worth £22m. ⁽¹⁸⁾AstraZeneca vaccine scientists set for £22m payday in New York float – Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public – TheGuardian – Apr 8, 2021}
Andrew J Pollard; Oxford COVID Vaccine Trial Group – Chair of the UK Department of Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI)
- Member of WHO’s SAGE
- National Institute for Health Research (NIHR) Senior Investigator.^{⁽¹⁹⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation}
Matthew D Snape– Grants from NIHR and non-financial support from AstraZeneca, during the conduct of the study
- Grants from Janssen
- Grants from GlaxoSmithKline
- Grants from Medimmune
- Grants from Novavax
- Grants from MCM
- Grants and non-financial support from Pfizer. ^{⁽²⁰⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation}
Johan Vekemans– employee of AstraZeneca. ^{⁽²¹⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation}
Tonya L Villafana– named as an inventor on a patent application covering this SARS-CoV-2 vaccine.
- A consultant to Vaccitech for an unrelated project, during the conduct of the study.
- Employee of AstraZeneca. ^{⁽²²⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation}

ANDREW POLLARD Prof

Lead developer of the Bexsero meningococcal B vaccine^{⁽²³⁾ Oxford University Case Study on MenB, Bexsero vaccine, Andrew Pollard: https://impact.ref.ac.uk/casestudies2/refservice.svc/GetCaseStudyPDF/15529}, previously owned by Novartis and now owned by GSK.
Chair of The Joint Committee on Vaccination & Immunisation (JCVI) ^{⁽²⁴⁾ Joint Committee Andrew Pollard on Vaccination and Immunisation: https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#membership}, who advises UK health departments on immunisation.
Director of the Oxford Vaccine Group (OVG) ^{⁽²⁵⁾ Oxford Vaccine Group Andrew Pollard: https://www.ovg.ox.ac.uk/team/andrew-pollard}, which received funding from vaccine manufacturers for their trials ^{⁽²⁶⁾ Oxford Vaccine Group COI: https://www.ovg.ox.ac.uk/about}.
Professor of Paediatric Infection and Immunity at the University of Oxford, which has significant financial influence from Vaccine Manufacturing and Innovation Centre UK ^{⁽²⁷⁾ Oxford University Financial Statements 2018/19: https://www.ox.ac.uk/sites/files/oxford/field/field_document/Oxford%20University%2C%20Financial%20Statement%202018-19_0.pdf Page 81 .}
Was chair of the European Medicines Agency, Scientific Advisory Group of Vaccines (ASAGV)^{⁽²⁸⁾ European Medicines Agency, Scientific Advisory Group of Vaccines: https://www.ema.europa.eu/en/committes/working-parties-other-groups/chmp/scientific-advisory-group-vaccines}, whose main stakeholders are pharmaceutical industries ^{⁽²⁹⁾European Medicines Agency, Scientific Advisory Group of Vaccines Stakeholders: https://www.ema.europa.eu/en/partners-networks/pharmaceutical-industry )).In 2016, became a member of the World Health Organisation (WHO) Scientific Advisory … Click for full citation}
Chaired the UK’s National Institute for Health and care Excellence (NICE) meningitis guidelines development group ^{⁽³⁰⁾ World Health Organisation, Member Andrew Pollard: https://www.who.int/immunization/sage/members/bio_pollard/en/}
Developer in AstraZeneca Oxford COVID-19 Vaccine^{⁽³¹⁾ AstraZeneca Oxford COVID-19 vaccine team, Andrew Pollard https://covid19vaccinetrial.co.uk/about .}

Declared Competing Interests in the AstraZeneca Trials Analysis

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 33306989; PMCID: PMC7723445.

Oxford University

Oxford University – Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. ⁽³²⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation
- Oxford University could also collect a big windfall, as it holds a 5.4% stake directly. It also owns further stakes through the university’s spin-out holding company, Oxford Sciences Innovation (OSI). ⁽³³⁾AstraZeneca vaccine scientists set for £22m payday in New York float – Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public – TheGuardian – Apr 8, 2021

Alexander D Douglas

Alexander D Douglas – reports grants and personal fees from AstraZeneca, outside of the submitted work. ⁽³⁴⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation

Pedro M Folegatti

Pedro M Folegatti – Consultant to Vaccitech during the conduct of the study. ⁽³⁵⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation

Adam Finn

Adam Finn – Member of the JCVI
- Chair of the WHO European Technical Advisory Group of Experts.
- Grants from Pfizer
- Grants from GlaxoSmithKline
- Grants from Sanofi
- Grants from Merck Sharp & Dohme
- Grants from Valneva. ⁽³⁶⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation

Sarah C Gilbert

Sarah C Gilbert – co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine (PCT/GB2012/000467). ⁽³⁷⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation
- Prof Sarah Gilbert, scientist who led the team that created the Oxford/AstraZeneca coronavirus vaccine, is set for a payday of more than £20m as the biotech firm she co-founded prepares to float on the stock market in the US.
- Gilbert owns 5.2% of Vaccitech, a Oxford University spin-out company that owns the biotechnology behind the AstraZeneca vaccine and others for MERS, hepatitis B, and a range of cancers. ⁽³⁸⁾ AstraZeneca vaccine scientists set for £22m payday in New York float – Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public – TheGuardian – Apr 8, 2021

Catherine Green

Catherine M Green – Clinical BioManufacturing Facility, University of Oxford, Oxford, UK.
- During the COVID-19 pandemic Green was part of the Oxford team who developed the Oxford–AstraZeneca COVID-19 vaccine. ⁽³⁹⁾Catherine M. Green – Wikipedia
- Reports personal fees from the Duke Human Vaccine Institute, outside of the submitted work. ⁽⁴⁰⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation

Adrian Hill

Hill AVS – AVSH reports personal fees from Vaccitech, outside of the submitted work, and has a patent on ChAdOx1 licensed to Vaccitech (PCT/GB2012/000467), will from royalty income to the University of Oxford from sales of this vaccine by AstraZeneca and sublicensees. ⁽⁴¹⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation Adrian Hill’s stakes could be worth £22m. ⁽⁴²⁾AstraZeneca vaccine scientists set for £22m payday in New York float – Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public – TheGuardian – Apr 8, 2021

Andrew J Pollard

Andrew J Pollard; Oxford COVID Vaccine Trial Group – Chair of the UK Department of Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI)
- Member of WHO’s SAGE
- National Institute for Health Research (NIHR) Senior Investigator. ⁽⁴³⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation

Matthew D Snape

Matthew D Snape– Grants from NIHR and non-financial support from AstraZeneca, during the conduct of the study
- Grants from Janssen
- Grants from GlaxoSmithKline
- Grants from Medimmune
- Grants from Novavax
- Grants from MCM
- Grants and non-financial support from Pfizer. ⁽⁴⁴⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation

Johan Vekemans

Johan Vekemans– employee of AstraZeneca. ⁽⁴⁵⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation

Tonya L Villafana

Tonya L Villafana– named as an inventor on a patent application covering this SARS-CoV-2 vaccine.
- A consultant to Vaccitech for an unrelated project, during the conduct of the study.
- Employee of AstraZeneca. ⁽⁴⁶⁾Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. … Click for full citation

Download Research

See All COVID Posts

Site Notifications/Chat:

Telegram Post Updates @JourneyToABetterLife (channel)
Telegram Chatroom @JourneyBetterLifeCHAT (say hi / share info)
Gettr Post Updates @chesaus (like fakebook)

Videos:

Aussies

Reveal PayID 323

Or Buy me a Coffee (PayPal)

References[+]

References
01	Andrew J Pollard – Prof of Paediatric Infection & Immunity – Director of The Oxford Vaccine Group – Member of the World Health Organisation’s SAGE, Chair of UK Health Department’s Joint Committee on Vaccination and Immunsation
02	WHO – SAGE – Immunization, Vaccines and Biologicals – Current SAGE Members (Archive.org copy) – Original URL keeps getting redirected to a “we are revamping our website” notice since April 25, 2021 https://www.who.int/immunization/sage/members/en/
03	Joint Committee Andrew Pollard on Vaccination and Immunisation: https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#membership
04	Financial Statements 2018/19 University of Oxford \| PDF P.81
05	Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 33306989; PMCID: PMC7723445.
06, 07	Financial Statements 2018/19 University of Oxford \| PDF P.81
08, 10, 11, 12	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 33306989; PMCID: PMC7723445.
09	AstraZeneca vaccine scientists set for £22m payday in New York float – Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public – TheGuardian – Apr 8, 2021
13, 17, 19, 20, 21, 22, 32, 34, 35, 36, 37, 41, 43, 44, 45, 46	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 33306989; PMCID: PMC7723445.
14	AstraZeneca vaccine scientists set for £22m payday in New York float – Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public – TheGuardian – Apr 8, 2021
15	Catherine M. Green – Wikipedia
16	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 33306989; PMCID: PMC7723445.
18, 33, 42	AstraZeneca vaccine scientists set for £22m payday in New York float – Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public – TheGuardian – Apr 8, 2021
23	Oxford University Case Study on MenB, Bexsero vaccine, Andrew Pollard: https://impact.ref.ac.uk/casestudies2/refservice.svc/GetCaseStudyPDF/15529
24	Joint Committee Andrew Pollard on Vaccination and Immunisation: https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#membership
25	Oxford Vaccine Group Andrew Pollard: https://www.ovg.ox.ac.uk/team/andrew-pollard
26	Oxford Vaccine Group COI: https://www.ovg.ox.ac.uk/about
27	Oxford University Financial Statements 2018/19: https://www.ox.ac.uk/sites/files/oxford/field/field_document/Oxford%20University%2C%20Financial%20Statement%202018-19_0.pdf Page 81
28	European Medicines Agency, Scientific Advisory Group of Vaccines: https://www.ema.europa.eu/en/committes/working-parties-other-groups/chmp/scientific-advisory-group-vaccines
29	European Medicines Agency, Scientific Advisory Group of Vaccines Stakeholders: https://www.ema.europa.eu/en/partners-networks/pharmaceutical-industry )). In 2016, became a member of the World Health Organisation (WHO) Scientific Advisory Group of Experts (SAGE) ^{(( World Health Organisation, Member Andrew Pollard: https://www.who.int/immunization/sage/members/bio_pollard/en/}
30	World Health Organisation, Member Andrew Pollard: https://www.who.int/immunization/sage/members/bio_pollard/en/
31	AstraZeneca Oxford COVID-19 vaccine team, Andrew Pollard https://covid19vaccinetrial.co.uk/about
38	AstraZeneca vaccine scientists set for £22m payday in New York float – Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public – TheGuardian – Apr 8, 2021
39	Catherine M. Green – Wikipedia
40	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 33306989; PMCID: PMC7723445.

Penny... on Health

Truth-seeker, ever-questioning, ever-learning, ever-researching, ever delving further and deeper, ever trying to 'figure it out'. This site is a legacy of sorts, a place to collect thoughts, notes, book summaries, & random points of interests.

DISCLAIMER: The information on this website is not medical science or medical advice. I do not have any medical training aside from my own research and interest in this area. The information I publish is not intended to diagnose, treat, cure or prevent any disease, disorder, pain, injury, deformity, or physical or mental condition. I just report my own results, understanding & research.

View my other posts